NAGE — Niagen Bioscience, Inc.

Nasdaq · Materials · Chemicals · CIK 1386570 ·
Last close
$3.45
Market Cap
$274.77M
52W High
$5.12
52W Low
$3.35
ADV30
991,720
Next earnings
2026-08-05
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 31,474,000 19,976,000 1,576,000 6,318,000 114,329,000 66,397,000 31,999,000
Dec 2025 33,839,000 21,704,000 2,103,000 4,132,000 106,406,000 64,636,000 29,873,000
Sep 2025 33,986,000 21,928,000 4,236,000 4,578,000 98,139,000 64,138,000 27,463,000
Jun 2025 31,117,000 20,226,000 3,185,000 3,609,000 91,525,000 60,322,000 27,330,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$13,504,000
Investing CF
$-292,000
Financing CF
$6,916,000
CapEx
$-292,000
Dividends Paid
Buybacks
EPS Diluted TTM
$0.20
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-164,528,000
Inventory
$20,424,000
Receivables
$9,741,000
ST Investments
EBIT TTM
$14,296,000
Pretax Income TTM
$18,192,000
Interest Exp TTM
Analysts
5

Yahoo Snapshot (yfinance, live)

Total Revenue
$130,416,000
EBITDA
$11,981,000
Free Cash Flow
$-1,861,500
Enterprise Value
$211,528,080
Total Cash
$66,397,000
Total Debt
$2,576,000
Shares Out
79,644,327
Trailing EPS
$0.21
Book Value
$1.03
ROE
27.1%
ROA
7.1%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 129,423,000 14,296,000 17,382,000 106,406,000 29,873,000 13,504,000
Dec 2024 99,597,000 7,726,000 8,550,000 68,278,000 22,184,000 12,109,000
Dec 2023 83,570,000 -5,599,000 -4,938,000 54,964,000 26,508,000 7,117,000
Dec 2022 72,050,000 -18,628,000 -16,540,000 54,057,000 25,385,000 -15,098,000

TTM Snapshot

Revenues TTM
$25,580,000
NetIncome TTM
$1,878,000
OpCashFlow TTM
$0
Assets (Latest)
$68,278,000
Forward EPS
$0.32

Max Pain — expiry 2026-08-21

max pain strike: $5.00 · spot: $3.52 · call oi: 1,924 · put oi: 222
Expected Move to 2026-08-21: ±$1.46 (41.34%) — implied range $2.06$4.97 · ATM straddle on $2.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
CRLBF Cresco Labs Inc. $290.46M $0.82
NL NL INDUSTRIES INC $295.84M $6.05
LTBR LIGHTBRIDGE Corp $308.74M $9.40
LODE Comstock Inc. $311.24M $4.10
GEVO Gevo, Inc. $340.78M $1.40

News headlines (Yahoo Finance, 1h cache)

Assessing Niagen Bioscience (NAGE) Valuation As It Renames Its NAD+ Research Program
2026-06-05 03:14 · Yahoo
Niagen Bioscience to Present at the 16th Annual East Coast IDEAS Investor Conference
2026-06-03 12:34 · Yahoo
How The Niagen Bioscience (NAGE) Investment Story Is Evolving Without New Analyst Signals
2026-06-02 15:10 · Yahoo
Niagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ Science
2026-06-02 12:32 · Yahoo
3 Growth Companies With High Insider Ownership And 15% Revenue Growth
2026-05-22 11:35 · Yahoo
How The Niagen Bioscience (NAGE) Story Is Shifting As Price Targets Edge Lower
2026-05-16 00:21 · Yahoo
3 Promising Penny Stocks With Market Caps Over $70M
2026-05-15 18:05 · Yahoo
Promising Penny Stocks To Consider In May 2026
2026-05-15 12:05 · Yahoo
Spotlight On Penny Stocks To Consider In May 2026
2026-05-14 18:05 · Yahoo
May 2026's Promising Penny Stocks
2026-05-14 12:04 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.